Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients

Rheumatology (United Kingdom)

Volumn 55, Issue 9, 2016, Pages 1673-1680

  Nagaraju, Kanneboyina ^a,b   Ghimbovschi, Svetlana ^a   Rayavarapu, Sree ^a,b   Phadke, Aditi ^a   Rider, Lisa G ^c   Hoffman, Eric P ^a,b   Miller, Frederick W ^c  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Biomarker; IFN signature; Myositis; Rituximab

Indexed keywords

ADAPTOR PROTEIN; CD19 ANTIGEN; CD68 ANTIGEN; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MYELOID TYPE 1 INTERFERON; PLACEBO; PREDNISONE; PROTEIN IPS 1; RITUXIMAB; SYNDECAN 1; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ACTIVITY; DNA MICROARRAY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MIDDLE AGED; MUSCLE BIOPSY; PHENOTYPE; POLYMYOSITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; TREATMENT RESPONSE; BONE MARROW CELL; GENETICS; METABOLISM; MULTIGENE FAMILY; MYOSITIS; PHYSIOLOGY; PLASMA CELL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; B-LYMPHOCYTES; FEMALE; HUMANS; INTERFERON TYPE I; MACROPHAGES; MALE; MIDDLE AGED; MULTIGENE FAMILY; MUSCLE, SKELETAL; MYELOID CELLS; MYOSITIS; PLASMA CELLS; RITUXIMAB; SYNDECAN-1;

EID: 84995646334     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew213     Document Type: Article

References (20)

1. Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011;305:183-90.
2. Rider LG, Giannini EH, Brunner HI et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-90.
3. Oddis CV, Reed AM, Aggarwal R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
4. Aggarwal R, Bandos A, Reed AM et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum 2013;66:740-9.
5. Reed AM, Peterson E, Bilgic H et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 2012;64:4078-86.
6. Nayak D, Johnson KR, Heydari S et al. Type I interferon programs innate myeloid dynamics and gene expression in the virally infected nervous system. PLoS Pathog 2013;9:e1003395.
7. Bilgic H, Ytterberg SR, Amin S et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60:3436-46.
8. O'Connor KA, Abbott KA, Sabin B, Kuroda M, Pachman LM. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006;120:319-25.
9. Dass S, Rawstron AC, Vital EM et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008;58:2993-9.
10. Rider LG, Yip AL, Horkayne-Szakaly I et al. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol 2014;32:689-96.
11. Salajegheh M, Kong SW, Pinkus JL et al. Interferonstimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010;67:53-63.
12. Baechler EC, Bauer JW, Slattery CA et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13:59-68.
13. Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis R. heum 2009;60:1815-24.
14. Greenberg SA. Type 1 interferons and myositis. Arthritis Res Ther 2010;12(Suppl 1):S4.
15. Walsh RJ, Kong SW, Yao Y et al. Type I interferoninducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784-92.
16. Raterman HG, Vosslamber S, de Ridder S et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012;14:R95.
17. Verweij CL, Vosslamber S. New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine. Discov Med 2011;12:229-36.
18. Nasr R, Reed AM, Peterson EJ. Update: biomarkers for idiopathic inflammatory myopathies. Curr Opin Rheumatol 2012;24:609-15.
19. Aggarwal R, Bandos A, Reed AM et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66:740-9.
20. Reed AM, Crowson CS, Hein M et al. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord 2015;16:257.